HUTCHMED (China) Limited (F:H7T1) — Market Cap & Net Worth
Market Cap & Net Worth: HUTCHMED (China) Limited (H7T1)
HUTCHMED (China) Limited (F:H7T1) has a market capitalization of $1.84 Billion (€1.57 Billion) as of September 16, 2026. Listed on the F stock exchange, this Germany-based company holds position #6469 globally and #956 in its home market, demonstrating a -2.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HUTCHMED (China) Limited's stock price €11.60 by its total outstanding shares 171950364 (171.95 Million). Also see total assets of HUTCHMED (China) Limited for a full breakdown of the balance sheet.
HUTCHMED (China) Limited Market Cap History: 2016 to 2026
HUTCHMED (China) Limited's market capitalization history from 2016 to 2026. Data shows change from $2.61 Billion to $2.33 Billion (-0.21% CAGR). Also see HUTCHMED (China) Limited (H7T1) cash flow conversion for how efficiently the company converts equity into cash flow.
HUTCHMED (China) Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HUTCHMED (China) Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check H7T1 stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.99x
HUTCHMED (China) Limited's market cap is 3.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.80x
HUTCHMED (China) Limited's market cap is 4.80 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.61 Billion | $216.08 Million | $11.70 Million | 12.06x | 222.85x |
| 2017 | $6.46 Billion | $241.20 Million | -$26.74 Million | 26.80x | N/A |
| 2018 | $4.27 Billion | $214.11 Million | -$74.81 Million | 19.96x | N/A |
| 2019 | $4.42 Billion | $204.89 Million | -$106.02 Million | 21.59x | N/A |
| 2020 | $4.70 Billion | $227.98 Million | -$125.73 Million | 20.63x | N/A |
| 2021 | $6.07 Billion | $356.13 Million | -$194.65 Million | 17.05x | N/A |
| 2022 | $2.85 Billion | $426.41 Million | -$360.83 Million | 6.69x | N/A |
| 2023 | $3.28 Billion | $838.00 Million | $100.78 Million | 3.91x | 32.51x |
| 2024 | $2.69 Billion | $630.20 Million | $37.73 Million | 4.27x | 71.40x |
| 2025 | $2.19 Billion | $548.51 Million | $456.91 Million | 3.99x | 4.80x |
Competitor Companies of H7T1 by Market Capitalization
Companies near HUTCHMED (China) Limited in the global market cap rankings as of September 16, 2026. Review H7T1 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to HUTCHMED (China) Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
HUTCHMED (China) Limited Historical Marketcap From 2016 to 2026
Between 2016 and today, HUTCHMED (China) Limited's market cap moved from $2.61 Billion to $ 2.33 Billion, with a yearly change of -0.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.33 Billion | +6.42% |
| 2025 | €2.19 Billion | -18.66% |
| 2024 | €2.69 Billion | -17.79% |
| 2023 | €3.28 Billion | +14.79% |
| 2022 | €2.85 Billion | -52.98% |
| 2021 | €6.07 Billion | +29.06% |
| 2020 | €4.70 Billion | +6.36% |
| 2019 | €4.42 Billion | +3.48% |
| 2018 | €4.27 Billion | -33.89% |
| 2017 | €6.46 Billion | +147.99% |
| 2016 | €2.61 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of HUTCHMED (China) Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.84 Billion USD |
| MoneyControl | $1.84 Billion USD |
| MarketWatch | $1.84 Billion USD |
| marketcap.company | $1.84 Billion USD |
| Reuters | $1.84 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more